Tocqueville Asset Management L.P. Sells 233,870 Shares of TScan Therapeutics, Inc. $TCRX

Key Points

• Tocqueville Asset Management L.P. sold 233,870 shares of TScan Therapeutics, reducing its holdings by 89.7% to 27,000 shares worth $37,000 by the end of the quarter.
• Several other institutional investors have made various adjustments to their stakes in TScan, with Bank of America increasing its holdings by 54.4% in the fourth quarter.
• TScan Therapeutics reported earnings of ($0.28) per share, meeting analyst expectations, with revenue of $3.08 million, significantly above the consensus estimate of $1.31 million.

Tocqueville Asset Management L.P. lowered its stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 89.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,000 shares of the company's stock after selling 233,870 shares during the period. Tocqueville Asset Management L.P.'s holdings in TScan Therapeutics were worth $37,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Lynx1 Capital Management LP raised its holdings in shares of TScan Therapeutics by 2.5% in the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock worth $16,286,000 after acquiring an additional 132,747 shares during the last quarter. Aberdeen Group plc raised its holdings in shares of TScan Therapeutics by 0.9% in the 1st quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock worth $1,230,000 after acquiring an additional 7,744 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of TScan Therapeutics by 108.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company's stock worth $851,000 after acquiring an additional 145,731 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of TScan Therapeutics by 54.4% in the 4th quarter. Bank of America Corp DE now owns 150,114 shares of the company's stock worth $456,000 after acquiring an additional 52,903 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of TScan Therapeutics by 5.2% in the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company's stock worth $404,000 after acquiring an additional 6,550 shares during the last quarter. Institutional investors and hedge funds own 82.83% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. HC Wainwright decreased their price objective on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Wedbush reiterated an "outperform" rating and issued a $7.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $7.80.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock traded up $0.04 on Thursday, reaching $1.74. 240,730 shares of the company traded hands, compared to its average volume of 254,189. TScan Therapeutics, Inc. has a 52 week low of $1.02 and a 52 week high of $6.2250. The company has a 50 day moving average of $1.68 and a 200 day moving average of $1.64. The firm has a market capitalization of $98.47 million, a PE ratio of -1.60 and a beta of 0.99. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.06 and a quick ratio of 7.06.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.28). The firm had revenue of $3.08 million during the quarter, compared to the consensus estimate of $1.31 million. TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. Equities analysts forecast that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.